Sugi Predict

Sugi Predict / Compounds / SCHEMBL2965385

SCHEMBL2965385

SCHEMBL2965385

COC(=O)C1=C(C)NC(C)=C(C(=O)Cl)C1c1cccc([N+](=O)[O-])c1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 3/20 0.78
▸ MEN1 O00255 3/20 0.78
▸ KMT2A Q03164 3/20 0.78
▸ MAPT P10636 3/20 0.78
▸ CYP1A2 P05177 2/20 0.78
▸ CYP3A4 P08684 2/20 0.78
▸ CYP2C9 P11712 2/20 0.78
▸ CYP2C19 P33261 2/20 0.78
▸ LMNA P02545 1/20 0.78
▸ POLB P06746 1/20 0.78
▸ MAPK1 P28482 1/20 0.78
▸ GPR55 Q9Y2T6 1/20 0.78
▸ CYP2D6 P10635 1/20 0.78
▸ TSHR P16473 1/20 0.78
▸ NFKB1 P19838 1/20 0.78
▸ THPO P40225 1/20 0.78
▸ NR3C2 P08235 1/20 0.77
▸ CACNA1F O60840 4/20 0.70
▸ CACNA1D Q01668 4/20 0.70
▸ CACNA1S Q13698 4/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30876840 1.00 HIF1A (0.78) HIF1AMEN1KMT2AMAPTCYP1A2
SCHEMBL10686311 1.00 HIF1A (0.78) HIF1AMEN1KMT2AMAPTCYP1A2
SCHEMBL15470499 1.00 HIF1A (0.78) HIF1AMEN1KMT2AMAPTCYP1A2
SCHEMBL30648615 0.94 HIF1A (0.87) HIF1AMEN1KMT2AMAPTCYP1A2
SCHEMBL6455299 0.94 HIF1A (0.87) HIF1AMEN1KMT2AMAPTCYP1A2
Hydrochloric Acid SCHEMBL9698949 0.93 HIF1A (0.85) HIF1AMEN1KMT2AMAPTCYP1A2
Hydrochloric Acid SCHEMBL4661064 0.93 HIF1A (0.85) HIF1AMEN1KMT2AMAPTCYP1A2
Hydrochloric Acid SCHEMBL10464260 0.93 HIF1A (0.85) HIF1AMEN1KMT2AMAPTCYP1A2
SCHEMBL9337172 0.91 HIF1A (0.78) HIF1AMEN1KMT2AMAPTCYP1A2
SCHEMBL9085813 0.91 HIF1A (0.81) HIF1AMEN1KMT2AMAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5912351-A 2,N-DIMETHYL-N-(3,3-DIPHENYLPROPYL)-1-AMINO-2-PROPANAL IN AN APROTIC SOLVENT REACTED WITH 2,6-DIMETHYL-5-METHOXYCARBONYL-4-(3-NITROPHENYL)-1,4-DIHYDROPYRIDINE-3 -CARBOXYLIC ACID; RECRYSTALLIZING LERCANIDIPINE CHLORIDE IN A SOLVENT MIXTURE RECORDATI, S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) 1999-06-15 — — US claimed
CN-117945985-A Preparation method of lercanidipine hydrochloride 福安药业集团重庆博圣制药有限公司 2024-04-30 — — CN disclosed
CN-117945985-A Preparation method of lercanidipine hydrochloride 福安药业集团重庆博圣制药有限公司 2024-04-30 — — CN disclosed
US-9198902-B2 1,4-dihydropyridine-3,5-dicarboxylate derivatives and preparation and use thereof Xuanzhu Pharma Co., Ltd. (CN) 2015-12-01 — — US disclosed
US-9198902-B2 1,4-dihydropyridine-3,5-dicarboxylate derivatives and preparation and use thereof Xuanzhu Pharma Co., Ltd. (CN) 2015-12-01 — — US disclosed
US-9198902-B2 1,4-dihydropyridine-3,5-dicarboxylate derivatives and preparation and use thereof Xuanzhu Pharma Co., Ltd. (CN) 2015-12-01 — — US disclosed
EP-2703398-A1 1,4-DIHYDROPYRIDINE -3,5-DICARBOXYLATE DERIVATIVES, PREPARATION METHODS AND USES THEREOF Xuanzhu Pharma Co., Ltd. (CN) 2014-03-05 — — EP disclosed
EP-2703398-A1 1,4-DIHYDROPYRIDINE -3,5-DICARBOXYLATE DERIVATIVES, PREPARATION METHODS AND USES THEREOF Xuanzhu Pharma Co., Ltd. (CN) 2014-03-05 — — EP disclosed
US-20140045896-A1 1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof Xuanzhu Pharma Co., Ltd. (CN) 2014-02-13 — — US disclosed
US-20140045896-A1 1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof Xuanzhu Pharma Co., Ltd. (CN) 2014-02-13 — — US disclosed
WO-2006134606-A1 A NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE HETERO DRUGS LIMITED (IN) 2006-12-21 — — WO disclosed
WO-2006134606-A1 A NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE HETERO DRUGS LIMITED (IN) 2006-12-21 — — WO disclosed
EP-1423367-B1 SOLVATES OF LERCANIDIPINE HYDROCHLORIDE AND CRYSTALLINE FORMS OF LERCANIDIPINE HYDROCHLORIDE RECORDATI IRELAND LTD (IE) 2005-04-27 — — EP disclosed
US-5286869-A Vasodilators and anticoagulants FUJIREBIO KABUSHIKI KAISHA (JP) 1994-02-15 — — US disclosed
EP-0320984-A2 1,4-Dihydropyridine derivatives FUJIREBIO INC. (JP) 1989-06-21 — — EP disclosed
US-4761420-A CARDIOVASCULAR DISORDERS LABORATOIRES SYNTEX S.A. (FR) 1988-08-02 — — US disclosed
EP-0249245-A2 Antihypertensive dihydropyridine derivatives LABORATOIRES SYNTEX S.A. (FR) 1987-12-16 — — EP disclosed
US-4672071-A Antihypertensive dihydropyridine compositions, optical isomers and intermediates SYNTEX (U.S.A.) INC. (US) 1987-06-09 — — US disclosed
US-4616002-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1986-10-07 — — US disclosed
EP-0191448-A2 Antihypertensive dihydropyridine derivatives SYNTEX (U.S.A.) INC. (US) 1986-08-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045896-A1 1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof PKD1, REN, GLS HIF1A 606/4885MEN1 137/4885KMT2A 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.